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p21/WAF1 was first isolated as one of the cyclin-dependent kinase
(cdk) interacting proteins induced by wild-type p53 (Matsushita
et al, 1996). The p53 gene is mutated in a large fraction of cancers,
suggesting that the expression of wild-type p53 gene is often rate-
limiting for tumour growth (Polyak et al, 1996). Its cell-cycle
inhibitory effects are mediated, at least in part, by transcriptional
activation of p21. Previous studies (Doglioni et al, 1996; Sasaki
et al, 1996) have also revealed differences in p21 and p53
expressions between normal mucosa, adenomas and adenocarci-
nomas of the large bowel. p21 expression is inversely related to
cell proliferation and directly related to terminal differentiation
(Doglioni et al, 1996). In addition, high p21 expression has been
associated with lower stage (Doglioni et al, 1996; Matsushita et al,
1996; Yasui et al, 1997) and lack of p53 overexpression, with
presumed p53 alteration resulting in loss of function (Doglioni et
al, 1996).
Activator protein (AP)-2 is a DNA-binding transcription factor
that activates p21 expression, providing a link between differenta-
tion and negative cell cycle control (Zeng et al, 1997; Gee et al,
1998). A number of genes functioning in ectodermally derived
tissues have been reported to be regulated by AP-2. A decrease in
AP-2 immunopositivity has been described in cervical intraepithe-
lial neoplasia (CIN) (Hietala et al, 1997). Similarly, in human
malignant melanoma, AP-2 expression levels were decreased
within tumours compared to strongly immunopositive normal
adjacent epidermis (Bar-Eli, 1997). In stage I cutaneous malignant
melanoma, reduced AP-2 expression is associated with malignant
transformation and tumour progression; furthermore, decreased
AP-2 expression is independently associated with elevated risk of
subsequent metastatatic behaviour and recurrent disease
(Karjalainen et al, 1998).
Prompted by the previously mentioned observations (Bar-Eli,
1997; Hietala et al, 1997; Zeng et al, 1997; Gee et al, 1998;
Karjalainen et al, 1998), we hypothesized that AP-2 might up-
regulate p21 and function as a tumour suppressor in colorectal
carcinoma. Therefore, clinicopathological parameters and prog-
nosis were statistically analysed in relation to p21, p53 and AP-2
protein levels in 162 colorectal carcinoma samples.
MATERIALS AND METHODS
Patients
The present study consists of 162 patients diagnosed and treated at
Kuopio University Hospital for colorectal adenocarcinoma
between 1976 and 1986, and subsequently followed-up for a mean
of 14.0 years. These patients were selected from the original
cohort of 308 patients from which 146 patients were excluded
because adequate histological material for p21, p53 and AP-2 was
not available any more. The excluded samples contained either a
rather small amount of tumour tissue or there was no tumour left in
the section. The clinical staging of all tumours was completed
according to UICC (Hermanek and Sobin, 1987) and modified
Dukes￿ classifications (Turnbull et al, 1967). Staging was based
on the results of abdominal ultrasonography, bone- and chest
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endoscopy (recto-sigmoidoscopy and colonoscopy) and laboratory
tests reflecting the possible metastasis. All 162 patients underwent
operations and, of these, 22 were additionally treated with
chemotherapy and 17 with radiotherapy. The follow-up was done
according to the standard practice used in our clinic by the same
team of gastroenterologists. The pertinent data of the patients are
summarized in Table 1.
Histology
The tumour samples obtained in the operation were immediately
fixed in 10% buffered formalin (pH 7.0), and later embedded in
paraffin. Several original sections from each of the primary
tumours were re-examined by two observers unaware of the clin-
ical data or the disease outcome, and the most representative tissue
block was selected, cut at 5-mm thickness and stained with
haematoxylin and eosin (H & E). Tumours were graded as well,
moderately, or poorly differentiated (WHO grade). The patients￿
histopathological data are shown in Table 1.
Immunohistochemistry and detection of p21, p53 and
AP-2
Five-micrometre-thick paraffin sections were rehydrated and
washed twice for 5 min with phosphate-buffered saline (PBS). The
sections were heated in a microwave oven in 0.05 mol l—1 Tris—HCl
buffer (pH 9.7) for 2 ´ 5 min. Endogenous peroxidase activity was
blocked with 5% hydrogen peroxide for 5 min, followed with a
wash for 2 ´ 5 min with PBS. The tissue sections were incubated
overnight at + 4°C with a p21-specific mouse monoclonal anti-
body (NCL-WAF-1, Novocastra Laboratories Ltd, UK) at a
working dilution of 1:10. Samples were washed twice for 5 min
with PBS and incubated for 30 min with biotinylated secondary
antibody (Vectastain ABC Elite Kit, Vector Laboratories,
Burlingame, CA, USA) in PBS. After two 5-min washings in PBS,
the sections were incubated for 40 min in avidin—biotin peroxidase
detection solution. Samples were washed 2 ´ 5 min with PBS,
developed with diaminobenzidine tetrahydrochloride (DAB;
Sigma, St Louis, MO, USA) for 5 min, slightly counterstained
with Mayers￿s haematoxylin, dehydrated, cleared and mounted
with DePex (BDH Supplies, Poole, UK).
The p53 immunoreactivity was demonstrated by means of
the same staining protocol. We used a monoclonal DO7 (Dako,
Denmark) antibody, known to be specific for both mutant and
wild-type forms of p53 protein at a working dilution of 1:1000.
For antigen retrieval the samples were boiled in a microwave oven
twice for 5 min in citrate buffer (pH 6.0).
The staining protocol for AP-2 has been published previously
(Hietala et al, 1997). After eliminating non-specific staining with
1.5% normal goat serum for 30 min, the tissue sections were incu-
bated overnight at +4°C with a primary antibody. We used a rabbit
polyclonal AP-2a (C-18) (Santa Cruz Biotechnology, Santa Cruz,
CA, USA) antibody, raised against a peptide corresponding to
amino acids 420—437 mapping at the carboxy terminus of AP-2 of
human origin, at a working dilution of 1:2500. After washings,
bound antibody was localized using the same method as described
above for p21. In each staining batch a section of human cutaneous
malignant melanoma (p21, AP-2) or colorectal carcinoma (p53)
with a known positivity for antibodies was used as a positive
control for p21, p53 and AP-2. Omission of the antibody served as
a negative control.
All slides were evaluated simultaneously with a dual-head
microscope (field diameter 490 mm) the observers (KMR and
VMK for p21 and AP-2; TP and VMK for p53) being unaware of
the clinical data. Disagreement in the assessment of staining was
found in fewer than 10% of the slides examined and consensus
was reached on further review. The staining intensity of p21, p53
and AP-2 in tumour epithelium and per cent distribution was
analysed from the most representative tissue section. p21 and p53
staining intensities in tumour epithelium were scored as follows: 
Absent staining was 0
If the staining intensity of tumour cell nuclei was clearly
weaker than the positive control, the staining intensity was
considered weak (1)
Moderate or strong (2) expression was defined as dark brown
staining comparable to the positive control
AP-2 intensity was either negative (0) or weak (1).
For evaluation of AP-2 expression, positive inflammatory cells
within the tumour and a section of human cutaneous melanoma
were used as positive controls. The fraction of positive tumour
cells was primarily analysed in a continuous scale but, for statis-
tical calculations, the percentage distribution of p21 and AP-2 was
divided into two groups using median as a cut-off level: † 10%,
> 10%, † 30%, > 30% respectively. Finally, the percentage
distribution of p53 was scored as previously: † 20%, > 20%
(Hirvikoski et al, 1997).
Analysis of lymphocyte density
The density of tumour-infiltrating lymphocytes (TILs) was graded
by two observers as absent, weak, moderate or dense, as described
previously (Ropponen et al, 1997). In brief, the TIL level was
quantified from ten microscopic fields (´40), and the mean TIL
value was calculated. TIL density was classified as absent (grade
0) when < 10 lymphocytes were observed per high-power field
(HPF). TIL density was weak (grade 1) when scanty lymphocytes
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Table 1 Clinicopathological data of the patients
Number of patients 162
Mean age of patients (± s.d.) (range) 65.4 (±11.0) (35.0–88.0)
Sex (females/males) (81/81)
Mean (± s.d.) follow-up years 14.0 (±3.8)
Type of primary treatment
Operation 162
Operation+chemotherapy 22
Operation+radiotherapy 17
Surgical treatment
Total colectomy 6
Hemicolectomy 40
Anterior resection of rectum 42
Abdominoperineal resection of rectum 31
Local excision 5
Resection of sigmoid 24
Exploratory laparotomy 14
T-category: Tis, 1, 2, 3, 4, X 2, 10, 26, 106, 16, 2
N-category: 0, 1, 2, 3, X 106, 32, 16, 4, 4
M-category: 0, 1 117, 45
Histological grade: 1, 2, 3 43, 96, 23
TIL grade: 0, 1, 2, 3 10, 100, 44, 8
Dukes’: 0, A, B, C, D 2, 27, 62, 26, 45were seen in the stroma and the inflammatory cell reaction around
the tumour was mild, i.e. 10—50 lymphocytes per HPF. TIL density
was moderate (grade 2) when peri- and/or intra-tumoural lympho-
cyte infiltrate was intermediate between grades 1 and 3, i.e.
lymphocyte level 51—100 per HPF. TIL density was dense (grade
3) when the tumour margins and stroma contained > 100 lympho-
cytes per HPF.
Mitotic indices
Mitotic figures were counted in the area of the highest mitotic
frequency, and ten consecutive high-power microscopic fields
(´40) were selected (field diameter 490 mm). The volume-
corrected mitotic index (M/V index) method was used in evalu-
ating the mitotic frequency as originally described (Haapasalo et
al, 1989). The M/V index expresses the number of mitotic figures
per mm2 of neoplastic epithelium in the microscopic image.
Statistical analysis
In statistical calculations, the SPSS-X programme package was
used in an IBM computer. The differences between the means
of continuous variables were tested by analysis of variance
(ANOVA), and the frequency distributions by the c2 test (Mantel
and Haenszel, 1992). The univariate survival analysis was based
on the life-table method (log-rank analysis) with statistics by
Gehan. Cancer-related survival was measured from the date of
surgery to the end of follow-up or death. Recurrence-free survival
(RFS) was defined as the time elapsed between the primary treat-
ment (date of surgery) and the date of recurrent tumour. Cases with
metastases at diagnosis were not included when the RFS was
analysed. The causes of death were verified from patient files and
death certificates. Multivariate survival analysis (Cox￿s regression
analysis) was performed with the SPSS-X programme package in
a step-wise manner (Cox, 1972), and P † 0.05 and P ‡ 0.01 were
statistically significant for entry and removal limits respectively.
Cox￿s proportional hazard model was used to assess the contribu-
tion of the following base-line covariates: age, sex, tumour grade,
tumour site (tumours involving rectum n = 78, or not n = 84),
Dukes￿ classification, TNM stage, TILs, p21, p53, AP-2 and M/V
index. In the survival analyses, low p53- and p21 intensities (0 and
1) were considered as one group, and moderate and strong inten-
sity (2) was considered as another group.
RESULTS
Expression of p21, p53, and AP-2
In normal mucosa adjacent to malignant tissue p21 immuno-
reactivity was observed mainly in the nuclei of the upper third of
the crypts and in the surface epithelium. p53 positivity was not
observed in the normal mucosa. AP-2 was expressed weakly in the
cytoplasm of normal intestinal epithelium. Twenty-five per cent
of the tumours were totally negative for p21, and 33% showed
moderate or strong expression intensity. Five per cent of the
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Figure 1 Immunohistochemical staining for p21 and AP-2 in human colon
carcinoma. (A) A sample with tumour cells intensely positive for p21. Note
the nuclear staining pattern (B) A sample with weak nuclear p21 staining
intensity in tumour cells. (C) A sample with cytoplasmic AP-2 staining in
tumour cells. Bar = 60 mm
Table 2 Expression of p21, p53 and AP-2 in colorectal cancer
Immunostaining Intensity (n) (%) Percentage fraction (n) (%)
p21 0 (40)  (25) ≤ 10 (81)  (50)
1  (69) (42) > 10  (81) (50)
2 (53)  (33)
p53 0 (8)  (5) ≤ 20 (35)  (22)
1  (67) (42) > 20 (127) (78)
2 (87)  (53)
AP-2 0 (18)  (11) ≤ 30 (74)  (46)
1 (144) (89) > 30  (88) (54)tumours were totally negative for p53, and 53% showed moderate
or strong expression intensity. AP-2 was negative in 11% of the
tumours, 89% of the tumours having a weak cytoplasmic AP-2
signal. Seventeen per cent of the tumours had nuclear positivity as
well (Figure 1) (Table 2).
Correlation of p21, p53, and AP-2 to other prognostic
factors
The expressions of p53 and p21 correlated inversely. As hypothe-
sized, the AP-2 and p21 expressions were positively associated
with each other (Tables 3 and 4). The percentage of p53-reacting
cells correlated inversely with p21 intensity (ANOVA, F = 5.24,
P = 0.006). The percentages of p53- and p21-reacting cells were
inversely interrelated (ANOVA, F = 4.23, P = 0.04). There were
no significant correlations between tumour grade and p21, p53 or
AP-2 expressions. In Dukes￿ A and B tumours, p21 expression
intensity and percentage distribution were higher in tumour epithe-
lium than in Dukes￿ C and D tumours (Table 3). p53 expression
intensity and percentage distribution in tumour epithelium and
AP-2 percentage distribution did not correlate with Dukes￿. No
significant associations were found between p53, AP-2 and TILs
or M/V index. p21 expression correlated with M/V index; low p21
signal was associated with high M/V index (Table 4).
Univariate survival analysis
In univariate survival analysis patients with negative or weak (0
and 1) p21 expression intensity in tumour epithelium had lower
survival and RFS rates as compared to patients with moderate or
strong p21 expression intensity (2) (Figures 2 and 3). p21
percentage distribution in tumour cells correlated with survival
and RFS as well. Patients with over 10% distribution of p21 had
higher survival and RFS rate as compared to patients with † 10%
distribution of p21 (Figures 4 and 5). Patients with negative or
weak (0 and 1) p53 expression intensity in tumour epithelium had
both higher survival and RFS rate as compared to patients with
moderate or strong p53 expression intensity (2) in their tumour
epithelium (c2 = 5.9, P = 0.01; c2= 8.9, P = 0.003 respectively).
p53 and AP-2 percentages were not related to cancer-related or
RFS (data not shown). In addition, the combination of the results
of p21 and p53 expression (p53—/p21—, p53+/p21—, p53—/p21+,
p53+/p21+) had no effect on survival or RFS in all patients or in
those with Dukes￿ B stage tumours, probably due to non-
comparable group sizes (data not shown).
T1—3/N0/M0 subgroup of patients with moderate or strong p21
expression intensity (2) in tumour epithelium had higher survival
rate (90% survived 10 years) as compared to patients with nega-
tive or weak p21 expression intensity (0 and 1) in their tumour
epithelium (35% survived 10 years) (c2 = 19.3, P < 0.001). Low
p21 expression intensity in tumour epithelium (0 and 1) predicted
poorer RFS rate (35% survived recurrence-free 10 years) as
compared to patients with moderate or strong p21 expression
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Table 3 Correlation between p21 expression intensity, percentage
distribution in tumour epithelium and Dukes’ classification, tumour grade and
p53
p21 intensity 0 1 2 p21%
n (%) n (%) n (%) (%) (± s.d.)
Dukes (n)
0 (2) 0 (0) 0 (0) 2 (4) 25 (7)
A (27) 1 (3) 7 (10) 19 (36) 30 (22)
B (62) 15 (37) 21 (30) 26 (49) 16 (17)
C (26) 10 (25) 10 (15) 6 (11) 12 (13)
D (45) 14 (35) 31 (45) 0 (0) 8 (10)
c2 = 50.7, P < 0.001a F = 8.3, P < 0.001b
Tumour grade (n)
1 (43) 10 (25) 14 (20) 19 (36) 18 (19)
2 (96) 24 (60) 42 (61) 30 (57) 14 (18)
3 (23) 6 (15) 13 (19) 4 (7) 13 (16)
c2 = 2.42, P = 0.11a F = 0.92, P = 0.40b
p53 intensity (n)
0 (8) 5 (13) 2 (3) 1 (2) 4 (7)
1 (67) 9 (23) 21 (30) 37 (70) 23 (20)
2 (87) 26 (64) 46 (67) 15 (28) 10 (14)
c2 = 34.6, P < 0.001a F = 8.3, P < 0.001b
ac2 test; b Analysis of variance.
Table 4 Correlation between p21, M/V index and AP-2 expression in
colorectal carcinoma
Variables n Spearman’s Two-tailed
correlation significance
coefficient
p21 vs. M/V index 162 –0.233 0.003
p21 vs. AP-2 162 0.195 0.013
p21 vs. p53 162 –0.114 0.018
p53 vs. M/V index 162 –0.003 0.971
p53 vs. AP-2 162 –0.014 0.836
AP-2 vs. M/V index 162 0.051 0.516
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Figure 2 The survival of 162 patients categorized according to the p21
expression intensity in tumour epithelium. The difference between the curves
is significant (c2 = 48.7, P < 0.001, Curve 0 and 1 = p21 intensity 0 and 1,
n = 109; curve 2 = p21 intensity 2, n = 53)intensity (2) in tumour epithelium (80% survived recurrence-free
10 years) (C2 = 14.0, P < 0.001). Similarly patients with low
percentage fraction of p21 († 10%) had lower RFS rate (35%
survived recurrence-free 10 years) as compared to patients with
high percentage fraction of p21 (> 10%) (70% survived recur-
rence-free 10 years) (C2 = 10.0, P = 0.002). Patients with negative
or weak p53 expression intensity in tumour epithelium (0 and 1)
survived longer as compared to patients with moderate or strong
(2) p53 expression intensity (C2 = 13.5, P = 0.004 and C2 = 4.2,
P = 0.04 for RFS).
Chemotherapy or radiation therapy in connection with primary
surgical therapy had no effect on survival. Chemotherapy or radia-
tion therapy for treatment of the recurrent disease had no prog-
nostic value since the therapies were given at a very late stage of
the disease as a palliative measure. In addition the type of surgery
had no effect on survival or RFS.
Multivariate analysis
The results of multivariate survival analyses are shown in Table 5.
In all patients p21 percentage in tumour epithelium predicted
survival significantly. In T1—4/N0—3/M0 and T1—3/N0/M0 patients
p21 expression intensity and p21 percentage in tumour epithelium
significantly predicted survival and RFS respectively. Accordingly,
in Dukes￿ B patients (n = 62) independent prognostic factors of
survival were tumour site (patients with their tumours located in
colon survived longer) (P = 0.04, relative risk (RR) = 0.36, 95%
confidence interval (CI) 0.14—0.95), M/V index (P = 0.009, RR =
1.15, 95% CI 1.04—1.28) and p21 expression intensity in tumour
epithelium (P < 0.001, RR = 0.33, 95% CI 0.17—0.63). In addition,
significant prognostic factors of RFS in Dukes￿ B patients (n = 62)
were tumour site (P = 0.006, RR = 0.33, 95% CI 0.15—0.73), TILs
(P = 0.007, RR = 0.33, 95% CI 0.15—0.73), M/V index (P = 0.03,
RR = 1.14, 95% CI 1.01—1.28) and p21 percentage in tumour
epithelium (P = 0.01, RR = 0.96, 95% CI 0.92—0.99).
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Figure 3 The recurrence-free survival of 117 patients categorized
according to the p21 expression intensity in tumour epithelium. The
difference between the curves is significant (c2 = 23.9, P < 0.001, Curve 0
and 1 = p21 intensity 0 and 1, n = 64; curve 2 = p21 intensity 2, n = 53)
Figure 5 The recurrence-free survival of 117 patients categorized
according to the p21 percentage fraction in tumour epithelium. The difference
between the curves is significant (c2 = 14.6, P < 0.001, Curve ≤ 10% = p21%
≤ 10, n = 51; curve > 10% = p21% > 10, n = 66)
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Figure 4 The survival of 162 patients categorized according to the p21
percentage fraction in tumour epithelium. The difference between the curves
is significant (C2 = 12.5, P < 0.001, Curve ≤ 10% = p21% ≤ 10, n = 81; curve
> 10% = p21% > 10, n = 81)DISCUSSION
In normal intestinal mucosa, p21 immunoreactivity has been mostly
observed in the nuclei of the upper third of the crypts and in the
surface epithelium (Doglioni et al, 1996; Sasaki et al, 1996; Yasui et
al, 1997), which is in line with our observation. In colorectal and
urothelial cancers, p21 expression has been reported to be hetero-
geneous and decreased compared to normal tissue (Doglioni et al,
1996; Sasaki et al, 1996; Clasen et al, 1998). The majority (75%) of
the tumours in our study showed p21 positivity, and 43% expressed
p21 moderately or strongly. The overexpression of p21 suppresses
tumour growth in several experimental models (Bae et al, 1995;
Chen et al, 1995; Li et al, 1995; Tenan et al, 1995). However, p21
overexpression has been associated with higher histological grade in
breast cancer and non-small-cell lung cancer (Caffo et al, 1996;
Bennett et al, 1998; Rey et al, 1998). In our study, p21 staining did
not correlate with tumour grade, which is in accordance with several
recent observations in different neoplasms (Doglioni et al, 1996;
Slebos et al, 1996; Byrne et al, 1997). Overexpression of p21 has
also been observed in low-grade (I—II) urothelial tumours (Clasen et
al, 1998). In addition, Doglioni et al (1996), Wang et al (1997) and
Yasui et al (1997) described higher p21 expression in stages 0—2
colon carcinomas than in stages 3 and 4 carcinomas. There is also
evidence supporting the hypothesis that p21 may exert its tumour
suppressive effects in the early stages of tumour development
(Ogawa et al, 1997; Clasen et al, 1998) to which the present study
gives further strengthening. However, some cancer studies have not
revealed any association between tumour stage and p21 expression
(Slebos et al, 1996; Byrne et al, 1997; Bennet et al, 1998). Taking
together the available information it is obvious that additional data
are needed to explain p21￿s multiplex functions more precisely
during cancer progression.
The relative p21 mRNA levels have been suppressed in tumours
with p53 mutations, indicating the necessicity of wild-type p53 for
p21 activation (Matsushita et al, 1996). In the present study, p21
overexpression correlated with low p53 level (by DO7 antibody),
which is in line with other recent papers (Doglioni et al, 1996;
Sasaki et al, 1996). Doglioni et al (1996) have suggested that high
p21 expression could be related to normal or increased p53 func-
tion, and low p21 expression could be related to inactivation of
p53 function. This, in other words, represents p53-dependent p21
induction pathway. Similar results were found in breast cancer by
Ellis et al (1997) and Bukholm et al (1997). Interestingly, DNA-
based mutational analysis did not reveal mutations to be respon-
sible for the changed regulatory effects of p53 in their study (Ellis
et al, 1997). It is important to remember that p53 overexpression
by immunohistochemistry may not necessarily represent mutated
p53, and furthermore, mutated p53 may still retain some trancrip-
tional activity (Doglioni et al, 1996).
Elsewhere p21 induction has been observed to be p53-indepen-
dent in breast cancer (Rey et al, 1998), ovarian cancer (Elbendary
et al, 1996; Anttila et al, 1999) and in human leukaemia (Zhang et
al, 1995). Our results suggested a p53-independent mechanism of
p21 activation only in a subgroup of patients (Table 3). This kind
of phenomenon (independent and dependent mechanisms) has also
been observed by Yasui et al (1997) in their series of colorectal
tumours. In addition, previous studies on endometrial (Backe et al,
1997; Ito et al, 1997), ovarian (Werness et al, 1997) and urothelial
carcinoma (Clasen et al, 1998) have failed to show a correlation
between p21 expression and p53. The significance of intra-
tumoural p21 and p53 staining heterogeneity can be hypothesized
as follows: a population of cancer cells with one functional copy
of p53 might still be able to activate p21 within a tumour in
which the other cells have already lost both functional copies.
Accordingly, p21 is weakly expressed in cells with one functional
allele of p53, and it is absent in cells with a mutation or loss of
both alleles (Sasaki et al, 1996). From previous studies it is known
that the immunoreactivity of p53 parallels the degree of mutation,
and weak staining of p53 indicates the presence of both wild-type
and mutant p53 proteins (Ohue et al, 1994). Based on the above
cited reports it is reasonable to suggest that p21 activation by p53
is complex, tissue-specific and may vary in different phases of cell
differentiation. Macleod et al (1995) showed that many adult
tissues expressed high levels of p21, including thymus, brain and
intestine as compared to liver, muscle and kidney. It is possible
that other cyclin—cdk inhibitors such as p27 are functioning in
these tissues to induce growth arrest prior to differentiation.
Alternatively these tissues may have reached a stable maintenance
of growth arrest (Macleod et al, 1995). Our results showed no p53
protein expression in epithelial cells of normal colorectal mucosa,
suggesting that p21 gene expression may occur by p53-indepen-
dent pathways in differentiated cells. This finding supports the
observation by Parker et al (1995) that increased levels of p21 may
also be linked with terminal differentiation of specialized cells.
Induction of p21 is thought to result in growth inhibition of
human cancer cells (Zeng et al, 1997). Different isoforms of tran-
scription factor AP-2 have been shown to activate the expression
of both positive and negative growth regulators, including c-erbB-
2 and p21WAF1/CIP1. In addition, in vitro and in vivo studies have
suggested that AP-2 may have the ability to restrict tumour growth
(Bar-Eli, 1997; Karjalainen et al, 1998). The strongest clinical
evidence for AP-2￿s tumour suppressive properties comes from the
study by Karjalainen et al (1998). While studying malignant
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Table 5 Independent predictors of survival and recurrence-free survival in
Cox’s analysis. Multivariate analysis included cases with a complete data set
available
Category b (s.e.) P Hazard rate (95% CI)
Survival
All cases (n = 162)
Dukes 0.688 (0.135) < 0.001 1.99 (1.53–2.60)
Grade 0.615 (0.230) 0.007 1.85 (1.18–2.90)
p21% –0.029 (0.011) 0.01 0.97 (0.95–0.99)
TILs –0.643 (0.232) 0.006 0.53 (0.33–0.83)
T1–4/N0–3/M0 (n = 117)
p21 intensity –0.712 (0.213) 0.001 0.49 (0.32–0.74)
M/V index 0.080 (0.036) 0.03 1.08 (1.01–1.16)
N-category 0.833 (0.256) 0.001 2.30 (1.39–3.80)
T1–3/N0/M0 (n = 84)
Age 0.075 (0.029) 0.01 1.08 (1.02–1.14)
Tumour site –1.022 (0.474) 0.03 0.36 (0.14–0.91)
M/V index 0.173 (0.055) 0.002 1.19 (1.07–1.32)
p21 intensity –1.105 (0.314) <0.001 0.33 (0.18–0.61)
Recurrence-free survival (n = 117)
T1–4/N0–3/M0
N-category 0.780 (0.217) <0.001 2.18 (1.43–3.34)
p21% –0.035 (0.011) 0.001 0.97 (0.94–0.99)
T1–3/N0/M0 (n = 84)
p21% –0.045 (0.014) 0.001 0.96 (0.93–0.98)
Significance level P < 0.05; b = coefficient of the regression model;
s.e. = standard error of b; CI = confidence intervalmelanomas they were able to show that AP-2 expression progres-
sively decreased as the tumour thickness increased (Karjalainen et
al, 1998). Decreasing AP-2 expression was also a strong predictor
for poor clinical outcome (Karjalainen et al, 1998). Further
evidence for AP-2￿s importance in cancer cell regulation is derived
from breast cancer studies where c-erbB-2 has been shown to be
regulated by AP-2 (Bosher et al, 1995). In this case overexpression
of c-erbB-2 is widely thought to contribute to poor clinical
outcome (Bosher et al, 1995). However, in the present series of
colorectal carcinoma, AP-2 staining did not reach prognostic
significance. Taken together, the data available so far suggest that
the effects of AP-2 are diverse and that different isoforms of AP-2
have different tissue specificity.
In the current study, p21 proved to be an antiproliferative factor;
it inversely correlated with mitotic index. Similarly, an inverse
correlation between p21 and Ki-67 proliferation antigen has
been documented recently in colorectal and endometrial cancer
(Doglioni et al, 1996; Palazzo et al, 1997). On the other hand,
several studies have not been able to demonstrate p21￿s antiprolif-
erative action (Backe et al, 1997; Diab et al, 1997; Werness et al,
1997). Accordingly, in breast cancer and malignant melanoma
increased cell proliferation has been positively related to p21
expression (Rey et al, 1998; Karjalainen et al, 1999). Possible
explanations in these cases include transient p21 expression before
entry into S phase, abnormal function of p21, or that tumour cells
have become refractory to inhibitory p21 signals.
Newly recognized cell cycle regulators were tested for their
relevance in predicting patients￿ clinical outcome in the present
study. Strong intensity and high percentage distribution of p21 in
tumour epithelium predicted longer survival and RFS time. In the
multivariate analysis, p21 expression intensity and percentage
distribution were independent prognostic factors for overall
survival and RFS. M/V index also proved to be a significant indi-
cator of survival in T1—4/N0—3/M0 and T1—3/N0/M0 cases. Our
results give further support for the previously documented role of
p21 as a negative growth regulator in colorectal cancer (Doglioni
et al, 1996; Sasaki et al, 1996; Yasui et al, 1997). p21 may inhibit
cancer spreading by suppressing abnormally accelerated cell
cycle, and may therefore be a good candidate for a new therapeutic
approach to control tumour cell growth. However, before being
ready for clinical testing, further studies explaining p21￿s possible
cell type specificity are needed.
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